Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TRPC5 | Q9UL62 | 12/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.49 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831879 | 0.86 | ALDH1A1 (0.69) | ALDH1A1TRPC5POLBKCNH2TRPC4 | |
| SCHEMBL20817993 | 0.86 | TRPC5 (0.76) | ALDH1A1TRPC5KCNH2TRPC4TIPARP | |
| SCHEMBL20831484 | 0.83 | TRPC5 (0.75) | ALDH1A1TRPC5POLBKCNH2TRPC4 | |
| SCHEMBL20831876 | 0.82 | ALDH1A1 (0.59) | ALDH1A1TRPC5POLBKCNH2TRPC4 | |
| SCHEMBL20831874 | 0.82 | ALDH1A1 (0.65) | ALDH1A1TRPC5POLBKCNH2TRPC4 | |
| SCHEMBL20818391 | 0.80 | ALDH1A1 (0.63) | ALDH1A1TRPC5POLBKCNH2TRPC4 | |
| SCHEMBL20817957 | 0.80 | ALDH1A1 (0.66) | ALDH1A1TRPC5POLBKCNH2TRPC4 | |
| SCHEMBL4813164 | 0.79 | ALDH1A1 (1.00) | ALDH1A1TRPC5POLBKCNH2TRPC4 | |
| SCHEMBL20831489 | 0.79 | ALDH1A1 (0.71) | ALDH1A1TRPC5POLBKCNH2TRPC4 | |
| SCHEMBL20831869 | 0.78 | ALDH1A1 (0.66) | ALDH1A1TRPC5POLBKCNH2TRPC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | ALDH1A1 649/4885TRPC5 1439/4885POLB 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.